Phosphorylation of its downstream effectors pS6 and pAKT (S473) was observed to be inhibited.37 RAD001 also prevented tumor growth of cells with HPV-negative TP53 mutation in vivo through autophagy activity.317 The novel mTOR inhibitors CZ415, AZD8055, OSI-027 (ASP4876), and CC-223 monotherapy inhibited HNSCC cell growth in vivo.318–320 mTOR monotherapy and combination with other treatment regimens all demonstrated promising effects on the HNSCC xenograft model. Here, MTOR is linked to neoplasm.